AU2003290642B2 - Precursor N-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme - Google Patents

Precursor N-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme Download PDF

Info

Publication number
AU2003290642B2
AU2003290642B2 AU2003290642A AU2003290642A AU2003290642B2 AU 2003290642 B2 AU2003290642 B2 AU 2003290642B2 AU 2003290642 A AU2003290642 A AU 2003290642A AU 2003290642 A AU2003290642 A AU 2003290642A AU 2003290642 B2 AU2003290642 B2 AU 2003290642B2
Authority
AU
Australia
Prior art keywords
sulfatase
acetylgalactosamine
fluid
precursor
rhasb
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2003290642A
Other languages
English (en)
Other versions
AU2003290642A1 (en
Inventor
Wai-Pan Chan
Lin Chen
Paul A. Fitzpatrick
John M. Henstrand
Minmin Qin
Christopher M. Starr
Stuart Swiedler
Dan J. Wendt
Gary N. Zecherle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomarin Pharmaceutical Inc
Original Assignee
Biomarin Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarin Pharmaceutical Inc filed Critical Biomarin Pharmaceutical Inc
Publication of AU2003290642A1 publication Critical patent/AU2003290642A1/en
Assigned to BIOMARIN PHARMACEUTICAL INC. reassignment BIOMARIN PHARMACEUTICAL INC. Amend patent request/document other than specification (104) Assignors: BIOMARIN PHARMACEUTICAL, INC.
Application granted granted Critical
Publication of AU2003290642B2 publication Critical patent/AU2003290642B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/32—Bonded phase chromatography
    • B01D15/325—Reversed phase
    • B01D15/327—Reversed phase with hydrophobic interaction
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3828—Ligand exchange chromatography, e.g. complexation, chelation or metal interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06012—N-Acetylgalactosamine-4-sulfatase (3.1.6.12)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
AU2003290642A 2002-11-07 2003-11-07 Precursor N-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme Expired AU2003290642B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/290,908 US6866844B2 (en) 2002-11-07 2002-11-07 Precursor N-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme
US10/290,908 2002-11-07
PCT/US2003/035510 WO2004043373A2 (en) 2002-11-07 2003-11-07 Precursor n-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme

Publications (2)

Publication Number Publication Date
AU2003290642A1 AU2003290642A1 (en) 2004-06-03
AU2003290642B2 true AU2003290642B2 (en) 2008-07-10

Family

ID=32312121

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003290642A Expired AU2003290642B2 (en) 2002-11-07 2003-11-07 Precursor N-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme

Country Status (17)

Country Link
US (1) US6866844B2 (enExample)
EP (2) EP2327414B1 (enExample)
JP (1) JP4459059B2 (enExample)
CN (1) CN100374157C (enExample)
AR (1) AR042019A1 (enExample)
AU (1) AU2003290642B2 (enExample)
BR (1) BRPI0316039B1 (enExample)
CA (1) CA2502928C (enExample)
CY (1) CY1116164T1 (enExample)
DK (1) DK2327414T3 (enExample)
ES (2) ES2533770T3 (enExample)
IL (1) IL168435A (enExample)
MX (1) MXPA05004880A (enExample)
PT (2) PT1565209E (enExample)
SI (1) SI2327414T1 (enExample)
TW (1) TWI327919B (enExample)
WO (1) WO2004043373A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6972124B2 (en) * 2000-05-01 2005-12-06 Biomarin Pharmaceuticals Inc. Precursor of N-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme
ES2366059T3 (es) * 2006-03-17 2011-10-14 Biomarin Pharmaceutical Inc. Ensayos para la detección de anticuerpos anti-enzimas lisosómicas.
CN101539550B (zh) * 2009-04-28 2012-05-23 李绍平 用于多糖的定性与定量分析方法
MX382443B (es) 2010-06-25 2025-03-11 Shire Human Genetic Therapies Una formulación estable para usarse en el tratamiento de la enfermedad por leucodistrofia metacromática (mld).
PE20130589A1 (es) * 2010-06-25 2013-05-19 Shire Human Genetic Therapies Composiciones y metodos para suministro al sistema nervioso central de arilsulfatasa a
CN103068999A (zh) * 2010-08-20 2013-04-24 贝林格尔.英格海姆国际有限公司 通过在获自细胞培养物的液体中改变ph灭活蛋白酶的方法
US9896715B2 (en) 2011-12-20 2018-02-20 Jcr Pharmaceuticals Co., Ltd. Method for analyzing formyl glycine residue
WO2013096899A2 (en) 2011-12-23 2013-06-27 Shire Human Genetic Therapies, Inc. Stable formulations for cns delivery of arylsulfatase a
CN105848746B (zh) * 2013-09-05 2019-07-09 豪夫迈·罗氏有限公司 用于层析重复利用的方法
FR3011468B1 (fr) * 2013-10-04 2015-12-04 Inventiva Utilisation de l'odiparcil dans le traitement d'une mucopolysaccharidose
US11584777B2 (en) 2017-08-31 2023-02-21 Green Cross Corporation Method for purifying a sulfatase protein
TWI870412B (zh) * 2019-06-05 2025-01-21 美商建南德克公司 過載層析管柱之再生方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL281225A (enExample) 1961-07-20
US3472931A (en) 1969-01-17 1969-10-14 Foster Milburn Co Percutaneous absorption with lower alkyl amides
US3891757A (en) 1971-11-11 1975-06-24 Alza Corp Anaesthetic topical and percutaneous administration with selected promoters
SE387536B (sv) 1973-03-13 1976-09-13 Astra Laekemedel Ab Forfarande for framstellning av en lokalanestetisk beredning
AU5577101A (en) 2000-05-01 2001-11-12 Biomarin Pharmaceuticals Enzymes useful for treating and methods for treating mps-vi and cells lines for producing such enzymes recombinantly

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Anson D. et al., Biochemistry Journal, 1992, Vol. 284, pages 789-794. *
Brooks D. et al., Biochimica Biophysica Acta, 1997, Vol. 1361, pages 203-216. *
Webb E. et al., Biotechnol. Appl. Biochem., 1996, Vol. 23, pages 205-207. *

Also Published As

Publication number Publication date
EP2327414B1 (en) 2015-01-07
CY1116164T1 (el) 2017-02-08
BR0316039A (pt) 2005-09-13
ES2445028T3 (es) 2014-02-27
AR042019A1 (es) 2005-06-08
US20040101524A1 (en) 2004-05-27
ES2533770T3 (es) 2015-04-15
CN1726046A (zh) 2006-01-25
PT1565209E (pt) 2014-02-13
EP1565209A2 (en) 2005-08-24
PT2327414E (pt) 2015-04-13
CN100374157C (zh) 2008-03-12
HK1157215A1 (en) 2012-06-29
BRPI0316039B8 (enExample) 2021-05-25
CA2502928C (en) 2013-07-16
MXPA05004880A (es) 2005-07-22
BRPI0316039B1 (pt) 2017-08-29
CA2502928A1 (en) 2004-05-27
EP1565209A4 (en) 2008-01-02
DK2327414T3 (en) 2015-04-13
TWI327919B (en) 2010-08-01
US6866844B2 (en) 2005-03-15
WO2004043373A2 (en) 2004-05-27
WO2004043373A3 (en) 2004-08-05
TW200427459A (en) 2004-12-16
SI2327414T1 (sl) 2015-05-29
IL168435A (en) 2014-07-31
EP1565209B1 (en) 2013-11-06
JP4459059B2 (ja) 2010-04-28
AU2003290642A1 (en) 2004-06-03
EP2327414A1 (en) 2011-06-01
JP2006510356A (ja) 2006-03-30

Similar Documents

Publication Publication Date Title
US20080260715A1 (en) Precursor N-acetylgalactosamine-4 sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme
AU2003290642B2 (en) Precursor N-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme
JP3857705B2 (ja) 組換えα−Ｌ−イズロニダーゼ、その生成及び精製方法及びその欠失により引き起こされる疾病の処理方法
WO2002038171A2 (en) METHODS FOR TREATING DISEASES CAUSED BY DEFICIENCIES OF α-L-IDURONIDASE
TWI877208B (zh) 人類重組精胺酸酶１之產生方法及其用途
CA2443555C (en) Enzymes useful for treating and methods for treating mps-vi and cells lines for producing such enzymes recombinantly
AU2001255771A1 (en) Enzymes useful for treating and methods for treating MPS-VI and cell lines for producing such enzymes recombinantly
JP6375112B2 (ja) テネクテプラーゼの医薬組成物
HK1079713B (en) Precursor n-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme
HK1079713A (en) Precursor n-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme
HK1157215B (en) Precursor n-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme
CN112210003A (zh) 一种重组载脂蛋白j及其类似物的晶体结构及应用
JP2022546587A (ja) 生物製剤の捕捉及び精製のための方法
HK40072878A (en) Method for capturing and purification of biologics
CN112245569A (zh) 一种稳定的阿柏西普制剂及其制备方法
Kakkis α-L-Iduronidase: the development of Aldurazyme (Laronidase)

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND CO-INVENTOR NAME FROM SWEIDLER, STUART TO SWIEDLER, STUART

TC Change of applicant's name (sec. 104)

Owner name: BIOMARIN PHARMACEUTICAL INC.

Free format text: FORMER NAME: BIOMARIN PHARMACEUTICAL, INC.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired